Business
CSL buys in to ‘long term’ haemophilia treatment in $655m deal – Sydney Morning Herald
The biotechnology giant has a plan to commercialise a treatment which could reduce treatments for haemophilia patients.
“Our vision with haemophilia B patients is to offer transformational treatment paradigms which help free them from the lifelong burden of this disease,” he said.
AMT-061 is an in-vivo gene therapy, …
Continue Reading
-
Noosa News20 hours agoMuster Dogs favourite Frank Finger makes final on-screen appearance with kelpie Annie in portrait show
-
General11 hours agoGoldfields man in coma after allegedly smashing head into ambulance windscreen
-
Business19 hours agoShould we be paying more attention to these two rocketing ASX small-cap mining stocks?
-
Noosa News21 hours agoWhy commuters are less likely to see familiar strangers on the bus, train or CityCat and why that makes us feel less safe